Accueil   Diary - News   All news Nosopharm raises €2.4 million ($2.6M) to develop a novel antibiotic class

Nosopharm raises €2.4 million ($2.6M) to develop a novel antibiotic class

Lyon, France, March 28, 2017 - Nosopharm, a biotechnology company specialized in the research and development of new antimicrobial molecules, today announces a financing round of €2.4 million ($2.6M), with Auriga Partners, Kreaxi and Alto Invest joining the company’s long-standing shareholders.

 

 

The funds raised will allow Nosopharm to accelerate the regulatory preclinical development of its first antibiotic molecule, NOSO-95179, which targets Enterobacteriaceae, a priority pathogen according to the WHO1 . First-in-man studies are expected to start in 2019.

 

 

Read the press release